Unintentional paediatric iron poisoning: A retrospective case series

Andrew K Crofton1,2, Keith Harris1,2,3, Carol Wylie3

  • 1Department of Emergency Medicine, Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Insights

Unintentional iron poisoning in children is rare and typically mild. Focus on symptomatic children for assessment and treatment to avoid unnecessary interventions.

Area of Science:

  • Pediatric Toxicology
  • Environmental Health
  • Public Health Measures

Background:

  • Iron poisoning historically significant for child morbidity and mortality.
  • Public health initiatives have reduced pediatric iron exposures.
  • Need for a specific assessment approach for unintentional pediatric iron poisoning.

Purpose of the Study:

  • Investigate unintentional iron poisoning in children.
  • Develop a tailored assessment approach for this demographic.
  • Evaluate predictors of toxicity in pediatric iron ingestions.

Main Methods:

  • Retrospective observational study.
  • Included children under 7 years old with unintentional iron poisoning.
  • Data sourced from poison information services, toxicology units, and medical records (2015-2020).

Main Results:

  • 54 children included; median age 2 years.
  • 17% were symptomatic; no severe toxicity cases.
  • Symptomatic children had significantly higher peak serum iron levels (66 μmol/L vs. 12 μmol/L).

Conclusions:

  • Unintentional pediatric iron poisoning is uncommon and generally benign.
  • Ingested dose is an unreliable predictor of toxicity.
  • Focusing on symptomatic children optimizes assessment and management.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
49
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
55
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
48
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.2K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
68
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
70